<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38329942</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2379-5077</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>19</Day></PubDate></JournalIssue><Title>mSystems</Title><ISOAbbreviation>mSystems</ISOAbbreviation></Journal><ArticleTitle>The function of the gut microbiota-bile acid-TGR5 axis in diarrhea-predominant irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>e0129923</StartPage><MedlinePgn>e0129923</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e01299-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/msystems.01299-23</ELocationID><Abstract><AbstractText Label="UNLABELLED">Imbalanced gut microbiota (GM) and abnormal fecal bile acid (BA) are thought to be the key factors for diarrhea-predominant irritable bowel syndrome (IBS-D), but the underlying mechanism remains unclear. Herein, we explore the influence of the GM-BA-Takeda G-protein-coupled receptor 5 (TGR5) axis on IBS-D. Twenty-five IBS-D patients and fifteen healthy controls were recruited to perform BA-related metabolic and metagenomic analyses. Further, the microbiota-humanized IBS-D rat model was established by fecal microbial transplantation (FMT) to investigate the GM-BA-TGR5 axis effects on the colonic barrier and visceral hypersensitivity (VH) in IBS-D. Finally, we used chenodeoxycholic acid (CDCA), an important BA screened out by metabolome, to evaluate whether it affected diarrhea and VH via the TGR5 pathway. Clinical research showed that GM associated with bile salt hydrolase (BSH) activity such as <i>Bacteroides ovatus</i> was markedly reduced in the GM of IBS-D, accompanied by elevated total and primary BA levels. Moreover, we found that CDCA not only was increased as the most important primary BA in IBS-D patients but also could induce VH through upregulating TGR5 in the colon and ileum of normal rats. TGR5 inhibitor could reverse the phenotype, depression-like behaviors, pathological change, and level of fecal BSH in a microbiota-humanized IBS-D rat model. Our findings proved that human-associated FMT could successfully induce the IBS-D rat model, and the imbalanced GM-BA-TGR5 axis may promote colonic mucosal barrier dysfunction and enhance VH in IBS-D.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Visceral hypersensitivity and intestinal mucosal barrier damage are important factors that cause abnormal brain-gut interaction in diarrhea-predominant irritable bowel syndrome (IBS-D). Recently, it was found that the imbalance of the gut microbiota-bile acid axis is closely related to them. Therefore, understanding the structure and function of the gut microbiota and bile acids and the underlying mechanisms by which they shape visceral hypersensitivity and mucosal barrier damage in IBS-D is critical. An examination of intestinal feces from IBS-D patients revealed that alterations in gut microbiota and bile acid metabolism underlie IBS-D and symptom onset. We also expanded beyond existing knowledge of well-studied gut microbiota and bile acid and found that <i>Bacteroides ovatus</i> and chenodeoxycholic acid may be potential bacteria and bile acid involved in the pathogenesis of IBS-D. Moreover, our data integration reveals the influence of the microbiota-bile acid-TGR5 axis on barrier function and visceral hypersensitivity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Kai</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8023-5015</Identifier><AffiliationInfo><Affiliation>Dongguan Hospital of Guangzhou University of Chinese Medicine, Dongguan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Haomeng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yongyin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Kehan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Shumin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yuanming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Dongguan Hospital of Guangzhou University of Chinese Medicine, Dongguan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weihuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shaogang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5507-1194</Identifier><AffiliationInfo><Affiliation>The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81974563, 81703992, 81904148</GrantID><Agency>MOST | National Natural Science Foundation of China (NSFC)</Agency><Country/></Grant><Grant><GrantID>No.SZ2022QN08</GrantID><Agency>Guangdong Provincial Academy of Chinese Medical Sciences</Agency><Country/></Grant><Grant><GrantID>202102010226, 202102010207, 2023A03J0733, 2023A03J0735</GrantID><Agency>Bureau of Science and Information Technology of Guangzhou Municipality | Guangzhou Municipal Science and Technology Project (Guangzhou Science and Technology Plan)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>mSystems</MedlineTA><NlmUniqueID>101680636</NlmUniqueID><ISSNLinking>2379-5077</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001647">Bile Acids and Salts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0GEI24LG0J</RegistryNumber><NameOfSubstance UI="D002635">Chenodeoxycholic Acid</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000649722">Bacteroides ovatus</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001647" MajorTopicYN="N">Bile Acids and Salts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002635" MajorTopicYN="N">Chenodeoxycholic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006967" MajorTopicYN="Y">Hypersensitivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001439" MajorTopicYN="Y">Bacteroides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TGR5</Keyword><Keyword MajorTopicYN="N">bile acid</Keyword><Keyword MajorTopicYN="N">diarrhea-predominant irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38329942</ArticleId><ArticleId IdType="pmc">PMC10949424</ArticleId><ArticleId IdType="doi">10.1128/msystems.01299-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. 2020. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 5:908&#x2013;917. doi:10.1016/S2468-1253(20)30217-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. 2016. Bowel disorders. Gastroenterology 139:1549&#x2013;155858. doi:10.1053/j.gastro.2016.02.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. 2022. Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis. Clin Gastroenterol Hepatol 20:136&#x2013;144. doi:10.1016/j.cgh.2020.09.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2020.09.043</ArticleId><ArticleId IdType="pubmed">33010413</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Wang H-F, Zhang Y, Zhang Y-L, Niu B-Y, Yao S-K. 2020. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol 26:7153&#x2013;7172. doi:10.3748/wjg.v26.i45.7153</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v26.i45.7153</ArticleId><ArticleId IdType="pmc">PMC7723672</ArticleId><ArticleId IdType="pubmed">33362374</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, Huang T, Ning Z, Zhai L, Zhong LL, et al. . 2020. A clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest 130:438&#x2013;450. doi:10.1172/JCI130976</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI130976</ArticleId><ArticleId IdType="pmc">PMC6934182</ArticleId><ArticleId IdType="pubmed">31815740</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao L, Liu Q, Luo M, Xiong L. 2021. Gut microbiota-derived metabolites in irritable bowel syndrome. Front Cell Infect Microbiol 11:729346. doi:10.3389/fcimb.2021.729346</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.729346</ArticleId><ArticleId IdType="pmc">PMC8495119</ArticleId><ArticleId IdType="pubmed">34631603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan K, Zheng H, Li J, Wu H, Qin S, Luo L, Huang S. 2020. Gut microbiota-bile acid crosstalk in diarrhea-irritable bowel syndrome. Biomed Res Int 2020:3828249. doi:10.1155/2020/3828249</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3828249</ArticleId><ArticleId IdType="pmc">PMC7676935</ArticleId><ArticleId IdType="pubmed">33274207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang X, Tian Z, Li L, Zeng Z, Chen M, Xiong L. 2018. Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front Microbiol 9:1600. doi:10.3389/fmicb.2018.01600</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01600</ArticleId><ArticleId IdType="pmc">PMC6068233</ArticleId><ArticleId IdType="pubmed">30090090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis ED, Antony JM, Crowley DC, Piano A, Bhardwaj R, Tompkins TA, Evans M. 2020. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of irritable bowel syndrome (IBS): a randomized, placebo-controlled study. Nutrients 12:1159. doi:10.3390/nu12041159</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12041159</ArticleId><ArticleId IdType="pmc">PMC7230591</ArticleId><ArticleId IdType="pubmed">32326347</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzyd&#x142;o-Radoma&#x144;ska B, Prozorow-Kr&#xf3;l B, Cicho&#x17c;-Lach H, Majsiak E, Bier&#x142;a JB, Kanarek E, Sowi&#x144;ska A, Cukrowska B. 2021. The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study. Nutrients 13:756. doi:10.3390/nu13030756</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13030756</ArticleId><ArticleId IdType="pmc">PMC7996889</ArticleId><ArticleId IdType="pubmed">33652763</ArticleId></ArticleIdList></Reference><Reference><Citation>Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. 2015. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 42:3&#x2013;11. doi:10.1111/apt.13227</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.13227</ArticleId><ArticleId IdType="pubmed">25913530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Wang H, Zhang Y, Zhang Y, Niu B, Chen S, Zhang W, Yao S. 2021. Faecal bile acids and colonic bile acid membrane receptor correlate with symptom severity of diarrhoea-predominant irritable bowel syndrome: a pilot study. Dig Liver Dis 53:1120&#x2013;1127. doi:10.1016/j.dld.2021.04.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2021.04.022</ArticleId><ArticleId IdType="pubmed">34053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayvargiya P, Camilleri M, Burton D, Busciglio I, Lueke A, Donato LJ. 2019. Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. Aliment Pharmacol Ther 49:744&#x2013;758. doi:10.1111/apt.15106</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15106</ArticleId><ArticleId IdType="pubmed">30740753</ArticleId></ArticleIdList></Reference><Reference><Citation>Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, Lamsam J, Singh R, Zinsmeister AR. 2010. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 8:159&#x2013;165. doi:10.1016/j.cgh.2009.10.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2009.10.020</ArticleId><ArticleId IdType="pmc">PMC2822105</ArticleId><ArticleId IdType="pubmed">19879973</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R, Zinsmeister AR. 2010. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139:1549&#x2013;1558. doi:10.1053/j.gastro.2010.07.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.07.052</ArticleId><ArticleId IdType="pmc">PMC3189402</ArticleId><ArticleId IdType="pubmed">20691689</ArticleId></ArticleIdList></Reference><Reference><Citation>Dior M, Delagr&#xe8;verie H, Duboc H, Jouet P, Coffin B, Brot L, Humbert L, Trugnan G, Seksik P, Sokol H, Rainteau D, Sabate J-M. 2016. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol Motil 28:1330&#x2013;1340. doi:10.1111/nmo.12829</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.12829</ArticleId><ArticleId IdType="pubmed">27060367</ArticleId></ArticleIdList></Reference><Reference><Citation>Masyuk TV, Masyuk AI, Lorenzo Pisarello M, Howard BN, Huang BQ, Lee P-Y, Fung X, Sergienko E, Ardecky RJ, Chung TDY, Pinkerton AB, LaRusso NF. 2017. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/G&#x3b1;s signaling. Hepatology 66:1197&#x2013;1218. doi:10.1002/hep.29284</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29284</ArticleId><ArticleId IdType="pmc">PMC5605412</ArticleId><ArticleId IdType="pubmed">28543567</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Cheng KC, Niu C-S, Lo S-H, Cheng J-T, Niu H-S. 2017. Investigation of triamterene as an inhibitor of the TGR5 receptor: identification in cells and animals. Drug Des Devel Ther 11:1127&#x2013;1134. doi:10.2147/DDDT.S131892</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S131892</ArticleId><ArticleId IdType="pmc">PMC5391213</ArticleId><ArticleId IdType="pubmed">28435224</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong J, Xia J. 2018. Metaboanalystr: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics 34:4313&#x2013;4314. doi:10.1093/bioinformatics/bty528</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty528</ArticleId><ArticleId IdType="pmc">PMC6289126</ArticleId><ArticleId IdType="pubmed">29955821</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BV, Begley M, Hill C, Gahan CGM, Marchesi JR. 2008. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A 105:13580&#x2013;13585. doi:10.1073/pnas.0804437105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804437105</ArticleId><ArticleId IdType="pmc">PMC2533232</ArticleId><ArticleId IdType="pubmed">18757757</ArticleId></ArticleIdList></Reference><Reference><Citation>James SC, Fraser K, Young W, Heenan PE, Gearry RB, Keenan JI, Talley NJ, Joyce SA, McNabb WC, Roy NC. 2021. Concentrations of fecal bile acids in participants with functional gut disorders and healthy controls. Metabolites 11:612. doi:10.3390/metabo11090612</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo11090612</ArticleId><ArticleId IdType="pmc">PMC8464974</ArticleId><ArticleId IdType="pubmed">34564428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen Z, Xia L, You H, Jingwei Z, Shasha Y, Xinyi W, Wenjing L, Xin Z, Chaomei F. 2021. An integrated gut microbiota and network pharmacology study on fuzi-lizhong pill for treating diarrhea-predominant irritable bowel syndrome. Front Pharmacol 12:746923. doi:10.3389/fphar.2021.746923</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.746923</ArticleId><ArticleId IdType="pmc">PMC8670173</ArticleId><ArticleId IdType="pubmed">34916934</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Wang P, Liu T, Lin L, Li L, Kou G, Zhou R, Li P, Li Y. 2021. Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome. BMC Microbiol 21:316. doi:10.1186/s12866-021-02380-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-021-02380-2</ArticleId><ArticleId IdType="pmc">PMC8590216</ArticleId><ArticleId IdType="pubmed">34773967</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY. 2015. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161:264&#x2013;276. doi:10.1016/j.cell.2015.02.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.02.047</ArticleId><ArticleId IdType="pmc">PMC4393509</ArticleId><ArticleId IdType="pubmed">25860609</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vos WM. 2013. Fame and future of faecal transplantations--developing next-generation therapies with synthetic microbiomes. Microb Biotechnol 6:316&#x2013;325. doi:10.1111/1751-7915.12047</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.12047</ArticleId><ArticleId IdType="pmc">PMC3917466</ArticleId><ArticleId IdType="pubmed">23574632</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, Huerta-Cepas J, Nieuwdorp M, Saloj&#xe4;rvi J, Voigt AY, Zeller G, Sunagawa S, de Vos WM, Bork P. 2016. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 352:586&#x2013;589. doi:10.1126/science.aad8852</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8852</ArticleId><ArticleId IdType="pubmed">27126044</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-Smith C, O&#x2019;Riordan KJ, Clarke G, Stanton C, Dinan TG, Cryan JF. 2020. Microbiota-gut-brain axis: new therapeutic opportunities. Annu Rev Pharmacol Toxicol 60:477&#x2013;502. doi:10.1146/annurev-pharmtox-010919-023628</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010919-023628</ArticleId><ArticleId IdType="pubmed">31506009</ArticleId></ArticleIdList></Reference><Reference><Citation>Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, Bunnett NW, Corvera CU. 2013. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144:145&#x2013;154. doi:10.1053/j.gastro.2012.09.055</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2012.09.055</ArticleId><ArticleId IdType="pmc">PMC6054127</ArticleId><ArticleId IdType="pubmed">23041323</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich M, Deutschmann K, Sommerfeld A, Klindt C, Kluge S, Kubitz R, Ullmer C, Knoefel WT, Herebian D, Mayatepek E, H&#xe4;ussinger D, Keitel V. 2016. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut 65:487&#x2013;501. doi:10.1136/gutjnl-2015-309458</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-309458</ArticleId><ArticleId IdType="pubmed">26420419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran X, Li Y, Chen G, Fu S, He D, Huang B, Wei L, Lin Y, Guo Y, Hu G. 2018. Farrerol ameliorates TNBS-induced colonic inflammation by inhibiting ERK1/2, JNK1/2, and NF-&#x3ba;B signaling pathway. Int J Mol Sci 19:2037. doi:10.3390/ijms19072037</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19072037</ArticleId><ArticleId IdType="pmc">PMC6073308</ArticleId><ArticleId IdType="pubmed">30011811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayama H, Okumura R, Takeda K. 2020. Interaction between the microbiota, epithelia, and immune cells in the intestine. Annu Rev Immunol 38:23&#x2013;48. doi:10.1146/annurev-immunol-070119-115104</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-070119-115104</ArticleId><ArticleId IdType="pubmed">32340570</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren T-H, Wu J, Yew D, Ziea E, Lao L, Leung W-K, Berman B, Hu P-J, Sung JJY. 2007. Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 292:G849&#x2013;56. doi:10.1152/ajpgi.00400.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00400.2006</ArticleId><ArticleId IdType="pubmed">17110521</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;nnikes H, Lauer G, Arnold R. 1997. Peripheral administration of cholecystokinin activates c-fos expression in the locus coeruleus/subcoeruleus nucleus, dorsal vagal complex and paraventricular nucleus via capsaicin-sensitive vagal afferents and CCK-A receptors in the rat. Brain Res 770:277&#x2013;288. doi:10.1016/s0006-8993(97)00865-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0006-8993(97)00865-2</ArticleId><ArticleId IdType="pubmed">9372230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>